NASDAQ:CALA - Calithera Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Calithera Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.15 -0.24 (-5.47 %) (As of 04/3/2020 02:06 PM ET) Add Compare Today's Range$4.15Now: $4.15▼$4.3150-Day Range$3.21MA: $5.69▼$7.8052-Week Range$2.45Now: $4.15▼$8.04Volume11,448 shsAverage Volume680,937 shsMarket Capitalization$268.42 millionP/E RatioN/ADividend YieldN/ABeta2.24 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALA Previous Symbol CUSIPN/A CIK1496671 Webhttp://www.calithera.com/ Phone650-870-1000Debt Debt-to-Equity Ratio0.05 Current Ratio8.14 Quick Ratio8.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.25 million Price / Sales12.06 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book1.85Profitability EPS (Most Recent Fiscal Year)($1.90) Net Income$-89,860,000.00 Net MarginsN/A Return on Equity-70.69% Return on Assets-58.60%Miscellaneous Employees79 Outstanding Shares64,680,000Market Cap$268.42 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive CALA News and Ratings via Email Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CALA Rates by TradingView Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions How has Calithera Biosciences' stock been impacted by COVID-19 (Coronavirus)? Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CALA stock has decreased by 20.7% and is now trading at $4.15. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Calithera Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Calithera Biosciences. When is Calithera Biosciences' next earnings date? Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Calithera Biosciences. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences Inc (NASDAQ:CALA) posted its quarterly earnings data on Wednesday, March, 11th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.02. View Calithera Biosciences' earnings history. What price target have analysts set for CALA? 5 analysts have issued 1-year price targets for Calithera Biosciences' stock. Their forecasts range from $6.00 to $7.00. On average, they expect Calithera Biosciences' stock price to reach $6.67 in the next year. This suggests a possible upside of 60.6% from the stock's current price. View analysts' price targets for Calithera Biosciences. Has Calithera Biosciences been receiving favorable news coverage? Press coverage about CALA stock has been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Calithera Biosciences earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCalithera Biosciences. Are investors shorting Calithera Biosciences? Calithera Biosciences saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,627,200 shares, an increase of 5.7% from the February 27th total of 1,540,000 shares. Based on an average daily volume of 433,500 shares, the days-to-cover ratio is currently 3.8 days. Approximately 4.7% of the shares of the stock are short sold. View Calithera Biosciences' Current Options Chain. Who are some of Calithera Biosciences' key competitors? Some companies that are related to Calithera Biosciences include ZEALAND PHARMA/S (ZEAL), Ligand Pharmaceuticals (LGND), CytoDyn (CYDY), Zogenix (ZGNX), Tricida (TCDA), TG Therapeutics (TGTX), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Heron Therapeutics (HRTX), Y-mAbs Therapeutics (YMAB), I-Mab (ARQT), Kiniksa Pharmaceuticals (KNSA), Madrigal Pharmaceuticals (MDGL) and Akebia Therapeutics (AKBA). What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and United Continental (UAL). Who are Calithera Biosciences' key executives? Calithera Biosciences' management team includes the following people: Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)Dr. Keith Orford, Chief Medical Officer (Age 47)Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)Ms. Jennifer McNealey, VP of Investor Relations & Strategy What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." How do I buy shares of Calithera Biosciences? Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $4.15. How big of a company is Calithera Biosciences? Calithera Biosciences has a market capitalization of $268.42 million and generates $22.25 million in revenue each year. The biotechnology company earns $-89,860,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe. View additional information about Calithera Biosciences. What is Calithera Biosciences' official website? The official website for Calithera Biosciences is http://www.calithera.com/. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected] MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 320 (Thanks for Voting!)Underperform Votes: 248 (Thanks for Voting!)Total Votes: 568MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/3/2020 by MarketBeat.com StaffFeatured Article: Purposes and Functions of the Federal Reserve
